Daiichi Sankyo to expand manufacturing equipment at Alphaville plant in Sao Paulo, Brazil
Pharma & MedicalBrazil
Daiichi Sankyo Brazil Ltda. plans to expand manufacturing equipment at its Alphaville plant in Sao Paulo, Brazil. The project has a total planned investment of ¥10.512 billion, with construction scheduled from June 2023 through April 2027; production capacity will be expanded after completion.
Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.
JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.
Lion has approved construction of a new pharmaceutical plant through its wholly owned Vietnamese subsidiary Merap Lion. The facility will produce prescription and over-the-counter solid-dose medicines, including tablets and granules, with operations planned to begin in the second half of 2030.
Tsumura will build a new QC building and hazardous-materials warehouse at its Ibaraki Plant in Ami, Ibaraki, to strengthen quality-testing capacity and business continuity for its kampo pharmaceutical products. Construction costs approximately ¥7 billion, designed and built by Kajima Corporation, with completion planned for mid-April 2028.
HOYA Lens Brazil plans to rationalize and expand manufacturing equipment for healthcare-related products at its Rio de Janeiro facility. The project is funded internally, with a total planned investment of JPY 1.027 billion; no construction schedule or capacity increase is disclosed.